MENU
JANX
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Janux Therapeutics (JANX) Ownership - Who owns Janux Therapeutics?
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer... Show more
Profile
Industry
N/A
Address
10955 Vista Sorrento Parkway
Phone
+1 858 751-4493
Employees
64
Web
https://www.januxrx.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
1.9B
P/E Ratio
N/A
Total Cash
1.03B
Projected Growth
N/A
Total Debt
23.03M
Revenue
10.59M
Risk (Beta)
3.29
Dividend Yield
N/A
Total Cash/Share
17.34
Total Debt/Equity
N/A
Revenue/Share
0.20 USD as % of share price
Fundamentals
JANX
Capitalization
1.9B
P/E Ratio
N/A
Risk (Beta)
3.29
Dividend Yield
N/A
Total Cash
1.03B
Total Cash/Share
17.34
Total Debt
23M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0.20%
Revenue
10.6M
ROE
N/A
Book Value
1.02B
P/B Ratio
1.85
Cash Flow
N/A
Earnings
-1.28
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
59K
Current Ratio
59.21
Current Revenue Per Employee
5776.32
Dividends Per Share - Security
N/A
EBITDA
-96.79M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-9.57
Shares Held By Institutions
4.56B
Shares Outstanding - Current
59.1M
Total Liabilities
38.7M
Total Volume MTD
N/A
Value
N/A
Gain YTD
-40.101
View a ticker or compare two or three
VS
VS
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information
General Information
Industry Biotechnology
Profile
Fundamentals
Details
Industry
N/A
Address
10955 Vista Sorrento Parkway
Phone
+1 858 751-4493
Employees
64
Web
https://www.januxrx.com